Aclarion, Inc. (NASDAQ:ACON) Short Interest Up 42.3% in October

Aclarion, Inc. (NASDAQ:ACON) was the target of a significant increase in short interest in the month of October. As of October 31st, there was short interest totalling 428,800 shares, an increase of 42.3% from the October 15th total of 301,400 shares. Based on an average trading volume of 609,700 shares, the short-interest ratio is currently 0.7 days. Approximately 4.5% of the company’s stock are sold short.

Aclarion Stock Performance

NASDAQ ACON opened at $0.17 on Thursday. The firm has a 50-day moving average of $0.18 and a 200-day moving average of $0.25. Aclarion has a 52-week low of $0.16 and a 52-week high of $7.40.

Aclarion (NASDAQ:ACON) last released its quarterly earnings results on Wednesday, August 14th. The company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. Aclarion had a negative net margin of 10,967.15% and a negative return on equity of 910.84%. The business had revenue of $0.01 million for the quarter. As a group, sell-side analysts expect that Aclarion will post -0.86 earnings per share for the current year.

Analyst Ratings Changes

Separately, Ascendiant Capital Markets restated a “buy” rating and issued a $1.50 price target (down from $1.60) on shares of Aclarion in a research note on Monday, August 26th.

Institutional Investors Weigh In On Aclarion

A hedge fund recently bought a new stake in Aclarion stock. Virtu Financial LLC purchased a new stake in Aclarion, Inc. (NASDAQ:ACON) during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 115,183 shares of the company’s stock, valued at approximately $38,000. Virtu Financial LLC owned about 1.40% of Aclarion as of its most recent filing with the Securities and Exchange Commission. 7.52% of the stock is owned by hedge funds and other institutional investors.

About Aclarion

Aclarion, Inc, a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software.